Keytruda Market trends
The Keytruda Market is shaped by several powerful trends that are redefining the oncology landscape. A dominant trend is the shift towards personalized medicine, where biomarkers like PD-L1 expression and tumor mutational burden are increasingly used to select patients most likely to respond to Keytruda. This targeted approach enhances treatment efficacy and reduces unnecessary costs and side effects. Another significant trend is the growing use of Keytruda in combination therapies. Ongoing clinical trials are exploring its use with chemotherapy, targeted therapies, and other immunotherapies to achieve synergistic effects and improve patient survival rates. This trend is not only expanding Keytruda's therapeutic utility but also creating new market segments.
The market is also trending towards the use of Keytruda in the adjuvant and neoadjuvant settings, where it is administered before or after surgery to treat early-stage or resectable cancers. This strategy aims to reduce the risk of recurrence and improve long-term survival, significantly expanding the patient population beyond advanced or metastatic disease. Furthermore, a key technological trend is the development of a subcutaneous (SC) formulation of Keytruda. This is a crucial development aimed at improving patient convenience and reducing administration time, a vital factor for a drug that is currently administered intravenously. The looming threat of biosimilar competition post-2028 is another major trend, forcing Merck to focus on lifecycle management strategies like t